Cargando…
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
BACKGROUND: For unresectable stage III non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC harboring driver-gene mutations benefit from Tyrosine Kinase Inhibitors (TKIs) Therapy. In a real-world setting, there is room for...
Autores principales: | Wu, Ranpu, Yu, Shaorong, Ye, Jinjun, Wang, Yimin, Zhao, Zhiting, Liu, Hongbing, Song, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311792/ https://www.ncbi.nlm.nih.gov/pubmed/34322390 http://dx.doi.org/10.3389/fonc.2021.692703 |
Ejemplares similares
-
Improved survival in patients with unresectable stage III EGFR
‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021) -
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
por: Luo, Laihui, et al.
Publicado: (2022) -
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018) -
Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021) -
Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)